Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy

Pyridoxal (PL) significantly suppresses PD-L1 expression.

• The interaction between PD-L1 and PD-1 is known to inhibit T cell activation.
• Higher levels of PD-L1 in tumor tissues may allow cancer cells to evade the immune system.
• PL accelerates the degradation of PD-L1 through a process that depends on the proteasome.
• STUB1 acts as an E3 ligase in the degradation of PD-L1 facilitated by PL.
• PL enhances the killing activity of T cells by blocking the PD-1/PD-L1 signaling pathway.
• PL is identified as a potential inhibitor of PD-L1, suggesting a new avenue for combination immunotherapy.

AI simplified